Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting Portfolio News / By Karina Tin April 19, 2023 Circle Pharma’s First-in-Class Orally Bioavailable Macrocyclic Cyclin A/B Inhibitors Highlighted in Poster Presentations at American Association for Cancer Research Annual Meeting Read More »
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting Portfolio News / By Karina Tin April 18, 2023 ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting Read More »
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations Portfolio News / By Karina Tin April 17, 2023 Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations Read More »
o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) Portfolio News / By Karina Tin April 16, 2023 o Accent Presentation: “Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer” (AACR 2023) Read More »
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 Portfolio News / By Karina Tin April 16, 2023 Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 Read More »
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin April 13, 2023 Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Read More »
Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California Portfolio News / By Karina Tin March 30, 2023 Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California Read More »
RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma Portfolio News / By Karina Tin March 29, 2023 RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma Read More »
Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer Portfolio News / By Karina Tin March 22, 2023 Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer Read More »
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Portfolio News / By Karina Tin March 22, 2023 Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Read More »
